Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.52 |
| ▸ | SYK | P43405 | 10/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CCNH | P51946 | 1/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245731 | 1.00 | HCRTR1 (0.52) | HCRTR1HCRTR2SYKCCNKCCNA2 | |
| SCHEMBL3717336 | 0.91 | DHFR (0.49) | HCRTR1HCRTR2SYKCCNKCCNA2 | |
| SCHEMBL3717341 | 0.91 | DHFR (0.49) | HCRTR1HCRTR2SYKCCNKCCNA2 | |
| SCHEMBL3718375 | 0.91 | SYK (0.47) | HCRTR1HCRTR2SYK | |
| SCHEMBL3718377 | 0.91 | SYK (0.47) | HCRTR1HCRTR2SYK | |
| SCHEMBL7271923 | 0.91 | GFER (0.47) | HCRTR1HCRTR2SYKCCNKCCNA2 | |
| SCHEMBL3804193 | 0.91 | GFER (0.47) | HCRTR1HCRTR2SYKCCNKCCNA2 | |
| SCHEMBL8218917 | 0.90 | HCRTR1 (0.49) | HCRTR1HCRTR2SYKCCNKCCNA2 | |
| SCHEMBL4249630 | 0.90 | HCRTR1 (0.46) | HCRTR1HCRTR2SYKCCNKCCNA2 | |
| SCHEMBL8227779 | 0.90 | HCRTR1 (0.46) | HCRTR1HCRTR2SYKCCNKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | claimed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | claimed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | HCRTR1 1/4885HCRTR2 2/4885SYK 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.